Aesculap, Inc. appears in FDA device records as the applicant behind a single premarket notification in this collection: K260044, covering Ventricular Catheters, Thomale Catheter. The filing sits in the neurology review panel under product code JXG, classified as a shunt, central nervous system and components device at Class II. The submission was received January 7, 2026 and decided October 2, 2026 as substantially equivalent, a traditional clearance with a summary statement and no third-party review. [1][5][9]
The documented device and its regulatory classification
The device named in the filing is Ventricular Catheters, Thomale Catheter. FDA records place it under product code JXG, regulation 21 CFR 882.5550, with the classification name Shunt, Central Nervous System And Components. The advisory committee and review panel are both listed as Neurology, and the device class is 2. The clearance type is Traditional, the statement or summary field reads Summary, and the third-party review flag is No. [1][5][9]
Independent indexes of the same FDA dataset describe the record the same way: K260044, Aesculap, Inc., product code JXG, decision SESE on October 2, 2026, received January 7, 2026, review panel Neurology. One index places the record within the neurology hierarchy under Subpart F, Neurological Therapeutic Devices, at 21 CFR 882.5550. [5][9]
Dated submission and decision
The premarket notification carries a receipt date of January 7, 2026 and a decision date of October 2, 2026. FDA's final-decision listing for 510(k)s rendered since October 1, 2026 records K260044 as Substantially Equivalent, published October 2, 2026, with the device and applicant named as Ventricular Catheters, Thomale Catheter and Aesculap, Inc. [1][6]
A third-party index reports the interval between receipt and decision as 268 days and states that no recalls are tied to the record in FDA's recall database. That review-time figure and the recall statement originate with that index, not with the FDA record itself. [7]
Applicant identity and registration records
The applicant name on K260044 is Aesculap, Inc., with a filing address of 3773 Corporate Pkwy., Center Valley, PA 18034, and a listed contact. A separate establishment registration record for AESCULAP, INC. shows an active registration at 615 Lambert Pointe Dr., Hazelwood, MO 63042, with the owner/operator listed at 3773 Corporate Pkwy. Filing addresses in FDA records are not headquarters designations, and the records do not establish a parent, brand or corporate hierarchy. [1][4]
The collection linked to this profile contains one 510(k) record, decided SESE, and no recall records. That count describes the filings assembled here as of the snapshot date; it is not a measure of the company's total portfolio, sales or safety performance. [1]
What the record does not establish
The numbered sources document a cleared catheter filing and a registration entry. They do not describe clinical performance, commercial availability, customers, certifications or manufacturing details for the Thomale Catheter, and none of those points should be inferred from the clearance alone. [1][4][5]

